Global Expansion BioArctic's partnership with Eisai and inclusion in China's insurance list highlight expanding market access in Asia, creating sales opportunities for localized product distribution and commercialization collaborations.

Innovative Treatment Pipeline The ongoing development of Leqembi® and subcutaneous dosing options offer potential for upselling and cross-selling advanced Alzheimer’s therapies to healthcare providers seeking emerging treatment modalities.

Regulatory Milestones Recent approvals and expanded indications in the UK, Canada, and the US demonstrate growing acceptance of BioArctic's treatments, signaling readiness for sales initiatives targeting neurologists and specialists in early Alzheimer’s disease.

Collaborative Opportunities Partnerships with large pharma companies like Novartis and Eisai open doors for joint sales efforts, technological licensing, and co-marketing strategies to penetrate key neurology markets.

Research and Data Presentation of long-term safety and efficacy data for lecanemab at conferences builds credibility and provides sales teams with strong evidence points to support clinician outreach and educational campaigns.